Search the Newsreel

MagnaChip Semiconductor Corp (MX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of MagnaChip Semiconductor Corp (MX), highlighting its current valuation score, P/E ratio, and ranking within the Semiconductors & Semiconductor Equipment industry. It notes that key valuation data like P/B, P/S, and P/CF have not yet been disclosed by …

MagnaChip Semiconductor Corp (MX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MagnaChip Semiconductor Corp (MX), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock's current price momentum score is 5.19, trading between resistance at $4.12 and support at $2.45. The analysis indicates …

FourWorld Capital Management LLC Raises Holdings in Magnachip Semiconductor Corp. $MX

FourWorld Capital Management LLC significantly increased its stake in Magnachip Semiconductor Corp. by 667.1% in the first quarter, now holding 4.55% of the company's shares. Institutional investors collectively own 74.26% of Magnachip, which has a "Hold" consensus rating and a $5.50 price target. The …

Free cash flow per share of Magnachip Semiconductor Corporation – HAM:SMG

This article provides access to the free cash flow per share data for Magnachip Semiconductor Corporation (HAM:SMG) on the Hamburg Stock Exchange via TradingView. It indicates that the market is currently closed with no trades recorded. The main focus is to present financial data …

Form 13D/A SMX (Security Matters) Public Limited Company For: 27 July

This article announces the filing of Form 13D/A by SMX (Security Matters) Public Limited Company, related to activity on July 27. It is a brief news item primarily indicating a regulatory filing, without providing further details about the content of the filing itself.

SMX (Security Matters) Public (SMX) grants CEO 100,000 RSUs

SMX (Security Matters) Public Ltd Co has granted its Chairman and CEO, Alon Haggai, 100,000 restricted stock units (RSUs) that vested immediately on July 23, 2026. This award increases his beneficial ownership to 277,440 ordinary shares. The shares from this grant are scheduled to …

SMX (Security Matters) PLC (SMX) Cash Flow

This article provides a detailed cash flow statement for SMX (Security Matters) PLC (SMX), covering annual and quarterly data across operating, investing, and financing activities. It presents financial figures for various periods, including percentage changes, and explains key cash flow metrics through an FAQ …

CytomX appoints Charles Fuchs to board of directors By Investing.com

CytomX Therapeutics has appointed Charles Fuchs, M.D., M.P.H., to its board of directors. Fuchs brings extensive experience from both the pharmaceutical industry, where he held senior roles at Genentech and Roche, and academia, having served as Director of the Yale Cancer Center. CytomX is …

4 Chemical Stocks Poised to Outshine Q2 Earnings Estimates

Chemical companies' second-quarter results are expected to reflect a recovery in demand in certain key markets and the end of customer inventory de-stocking. Improved demand in automotive and a rebound in construction end markets are likely to have supported their performance. The results of …

Charles Fuchs appointed to CytomX Board as Class II director

CytomX Therapeutics (CTMX) has appointed Charles Fuchs as a Class II director, effective July 24, 2026, with his term extending through the 2029 annual meeting. As part of his compensation, he will receive standard non-employee director compensation and an option for 118,000 shares which …

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CytomX Therapeutics has appointed Charles Fuchs, M.D., M.P.H., a board-certified medical oncologist with over three decades of oncology leadership experience, to its Board of Directors. Dr. Fuchs' extensive background in oncology product development, including his expertise in gastrointestinal oncology, is expected to be invaluable …

SMX|SMX (Security Matters) PLC|Price:17.325|Chg%:-0.225

This article provides a detailed explanation of TradingKey's comprehensive Stock Score for SMX (Security Matters) PLC, covering six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. It outlines the methodologies used to calculate each score dimension, emphasizing …

SMX (Security Matters) PLC (SMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on the revenue breakdown of SMX (Security Matters) PLC (SMX), covering business segments, regional revenue, and profit contribution. It notes that relevant financial data for these categories has not yet been disclosed by the company. The page provides current …

MagnaChip Semiconductor Corp (MX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of MagnaChip Semiconductor Corp's (MX) shareholder structure, including major shareholders, shareholder types, and institutional holdings. It lists the top individual and institutional shareholders with their respective proportions and recent changes, as well as the types of entities holding …

MX|MagnaChip Semiconductor Corp|Price:3.500|Chg%:-0.150

This article provides a detailed financial overview of MagnaChip Semiconductor Corp (MX), including its financial summary, income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings date, EPS forecast, and various financial indicators and ratios across multiple quarters and fiscal …

CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for CytomX Therapeutics Inc (CTMX). It indicates that the company has not yet disclosed relevant data for fiscal years, quarters, or by business segment. The available regional revenue data shows United States contributing $76.20 million, but …

CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for CytomX Therapeutics Inc (CTMX). It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock data, including its market capitalization, …

CTMX|CytomX Therapeutics Inc|Price:3.240|Chg%:-0.090

CytomX Therapeutics Inc. (CTMX) is a clinical-stage oncology biopharmaceutical company specializing in conditionally activated, masked biologics through its PROBODY therapeutic platform. The company's pipeline includes therapeutic candidates like ADCs, T-cell engagers, and immune modulators such as CX-2051, CX-904, and CX-801. The article provides detailed …

SMX Balance Sheet

This article provides the balance sheet for SMX (Security Matters) PLC, allowing users to evaluate financial health and key ratios. It presents quarterly and annual financial statements, including detailed data on assets, liabilities, and shareholders' equity. The document also includes an FAQ section addressing …

MagnaChip Semiconductor Corp

This article provides a revenue breakdown for MagnaChip Semiconductor Corp (MX), detailing its financial performance by region. Key revenue contributions are from South Korea, Asia Pacific, USA, and Europe. The report also notes that relevant data for business segments have not yet been disclosed …

MagnaChip Semiconductor Corp (MX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of MagnaChip Semiconductor Corp (MX) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. Key financial data like market cap, stock price, and P/E …

TradingKey

This article provides a detailed income statement for CytomX Therapeutics Inc (CTMX) from FY2014Q1 to FY2026Q1, highlighting various financial metrics such as total revenue, operating expenses, research & development expenses, and net income. It also includes frequently asked questions about interpreting income statements on …

SMX (Security Matters) PLC (SMX) Income Statement

Methanex Corporation Revenue Breakdown – TSX:MX

SMX (Security Matters) PLC (SMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of SMX (Security Matters) PLC (SMX), outlining its support, resistance, indicators, and moving averages. It includes a summary of both individual technical indicators, which show mixed signals with more sells and neutrals than buys, and moving averages, which …

What Navitas Semiconductor (NVTS)'s SiC Licensing Deal With Magnachip Means For Shareholders

Navitas Semiconductor's new licensing deal with Magnachip Semiconductor, allowing Magnachip to produce Navitas' GeneSiC Trench-Assisted Planar silicon carbide technology, is an incrementally positive development for Navitas' SiC roadmap. This partnership expands Navitas' reach into high-voltage power markets and aims to reinforce its position in …

CytomX Therapeutics Inc (CTMX) Institutional Confidence

CytomX Therapeutics Inc (CTMX) holds an institutional shareholding score of 7.00, ranking 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 78.87%, reflecting a 19.41% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 9.71 million shares.

Navitas Magnachip SiC Partnership Accelerates High-Voltage Power Semiconductor Innovation

Navitas Semiconductor and Magnachip Semiconductor have announced a strategic partnership to advance silicon carbide (SiC) technology in high-voltage and ultra-high-voltage power markets. Magnachip will license Navitas’ GeneSiC™ Trench-Assisted Planar TM (TAP) technology, covering various high-voltage SiC technologies, and will gain access to Navitas’ supply …

MagnaChip Semiconductor (MX.US) will release its earnings report after market close on July 29.

MagnaChip Semiconductor (MX.US) is scheduled to release its earnings report after the market closes on July 29.

Magnachip licenses Navitas GeneSiC technology in high-voltage silicon carbide partnership

Magnachip has formed a strategic partnership with Navitas to accelerate the adoption of high-voltage silicon carbide power semiconductors. This deal grants Magnachip access to Navitas' GeneSiC Trench-Assisted Planar technology and its silicon carbide supply chain, with the technology to be implemented at Magnachip's South …

BRIEF-Navitas And Magnachip Announce Strategic Partnership To Accelerate High-Voltage And Ultra-High-Voltage Silicon Carbide Adoption

Navitas and MagnaChip Semiconductor Corp have announced a strategic partnership aimed at accelerating the adoption of high-voltage and ultra-high-voltage silicon carbide (SiC) devices. Under this agreement, MagnaChip will license Navitas' GeneSiC technology for SiC devices ranging from 1200V to 3300V and higher. The partnership …

Magnachip Plans to Internalize Silicon Carbide Tech at Korea Fab

Navitas Semiconductor and Magnachip Semiconductor have announced a strategic partnership to accelerate the adoption of silicon carbide (SiC) in high-voltage power markets. Under the agreement, Magnachip will license Navitas’ GeneSiC Gen 4 and Gen 5 Trench-Assisted Planar SiC technologies, covering a range of voltages, …

Did Methanex’s Dividend Reaffirmation and Brighter Earnings Outlook Just Shift Its (TSX:MX) Investment Narrative?

Magnachip Semiconductor (MX) Projected to Announce Earnings on Wednesday

Methanex (TSX:MX) Dividend Update Leaves Its Undervalued Narrative In Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Methanex (TSX:MX) recently affirmed its shareholder return policy, with the Board declaring a quarterly dividend of US$0.185 per share. The dividend is payable …

Does Methanex (TSX:MX) Dividend Stability Reveal a Mature Capital Strategy or Untapped Growth Ambition?

Methanex Corporation's Board of Directors previously declared a quarterly dividend of US$0.185 per share, payable on September 30, 2026 to shareholders of record on September 16, 2026, underscoring ongoing cash returns to investors. This dividend, alongside the company's improved operations, better natural gas availability …